# Merrimack Pharmaceuticals Inc. (MACK)

Source: https://www.quantisnow.com/company/MACK
Generated: 2026-11-08T22:21:35.449Z

- Ticker: MACK
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2012
- Website: merrimack.com

## About

Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was founded in 1993 and is headquartered in Cambridge, Massachusetts.

## Latest MACK news and filings

- 2024-05-20 20:05 UTC [SEC Form 15-12G filed by Merrimack Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-15-12g-filed-by-merrimack-pharmaceuticals-inc-5503989)
- 2024-05-15 20:15 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Merrimack Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-merrimack-pharmaceuticals-inc-5493669)
- 2024-05-14 06:20 UTC [Leadership Update] [Vicore Expands and Strengthens its Board of Directors](https://www.quantisnow.com/insight/vicore-expands-and-strengthens-its-board-of-directors-5486758)
- 2024-05-10 20:45 UTC [SEC Form 25 filed by Merrimack Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-25-filed-by-merrimack-pharmaceuticals-inc-5482420)
- 2024-05-10 20:43 UTC [SEC Form 8-K] [SEC Form 8-K filed by Merrimack Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-merrimack-pharmaceuticals-inc-5482393)
- 2024-05-10 20:36 UTC [Market Chatter] [Merrimack Pharmaceuticals Announces Approval Of Plan Of Dissolution And Cash Liquidating Dividend Amount Of $15.10 Per Share](https://www.quantisnow.com/insight/merrimack-pharmaceuticals-announces-approval-of-plan-of-dissolution-and-cash-5482333)
- 2024-05-10 20:30 UTC [Dividends] [Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock](https://www.quantisnow.com/insight/merrimack-pharmaceuticals-inc-announces-stockholder-approval-of-plan-of-dissolution-5482180)
- 2024-05-09 11:45 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Merrimack Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-merrimack-pharmaceuticals-inc-5475251)
- 2024-05-09 11:43 UTC [SEC Form 8-K] [SEC Form 8-K filed by Merrimack Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-merrimack-pharmaceuticals-inc-5475241)
- 2024-05-09 11:30 UTC [Dividends] [Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Subject to Receipt of Stockholder Approval of Plan of Dissolution](https://www.quantisnow.com/insight/merrimack-pharmaceuticals-inc-announces-anticipated-final-cash-dividend-amount-of-5475126)
- 2024-04-30 21:40 UTC [Market Chatter] [Merrimack Pharmaceuticals To Voluntary Delist Common Stock On NASDAQ](https://www.quantisnow.com/insight/merrimack-pharmaceuticals-to-voluntary-delist-common-stock-on-nasdaq-5446345)
- 2024-04-30 21:24 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Merrimack Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-merrimack-pharmaceuticals-inc-5446237)
- 2024-04-30 21:22 UTC [SEC Form 8-K] [SEC Form 8-K filed by Merrimack Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-merrimack-pharmaceuticals-inc-5446215)
- 2024-04-30 21:15 UTC [Dividends] [Merrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of Dissolution](https://www.quantisnow.com/insight/merrimack-pharmaceuticals-announces-notification-of-plan-to-voluntary-delist-common-5446147)
- 2024-04-01 20:28 UTC [SEC Form DEFR14A filed by Merrimack Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-defr14a-filed-by-merrimack-pharmaceuticals-inc-5381158)
- 2024-03-27 21:00 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Merrimack Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-merrimack-pharmaceuticals-inc-5372854)
- 2024-03-27 20:57 UTC [SEC Form 8-K] [Merrimack Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure](https://www.quantisnow.com/insight/merrimack-pharmaceuticals-inc-filed-sec-form-8-k-regulation-fd-disclosure-5372841)
- 2024-03-27 20:34 UTC [Market Chatter] [Merrimack Secures $225M Milestone Payment From Ipsen; Says It Is Unlikely That Any Additional Milestone Payments Will Become Payable](https://www.quantisnow.com/insight/merrimack-secures-225m-milestone-payment-from-ipsen-says-it-is-5372661)
- 2024-03-22 13:46 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Merrimack Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-merrimack-pharmaceuticals-inc-5362977)
- 2024-03-21 20:52 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Merrimack Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-merrimack-pharmaceuticals-inc-5361660)
- 2024-03-21 20:48 UTC [SEC Form 10-K] [SEC Form 10-K/A filed by Merrimack Pharmaceuticals Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-10-ka-filed-by-merrimack-pharmaceuticals-inc-amendment-5361630)
- 2024-03-07 21:42 UTC [SEC Form 425] [SEC Form 425 filed by Merrimack Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-425-filed-by-merrimack-pharmaceuticals-inc-5327635)
- 2024-03-07 21:39 UTC [SEC Form 8-K] [Merrimack Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure](https://www.quantisnow.com/insight/merrimack-pharmaceuticals-inc-filed-sec-form-8-k-regulation-fd-disclosure-5327614)
- 2024-03-07 21:34 UTC [Market Chatter] [Merrimack FY23 EPS $(0.08) Per Basic Share](https://www.quantisnow.com/insight/merrimack-fy23-eps-008-per-basic-share-5327446)
- 2024-03-07 21:30 UTC [Dividends] [Merrimack Reports Full Year 2023 Financial Results](https://www.quantisnow.com/insight/merrimack-reports-full-year-2023-financial-results-5327345)
- 2024-03-07 21:15 UTC [SEC Form 10-K] [SEC Form 10-K filed by Merrimack Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-10-k-filed-by-merrimack-pharmaceuticals-inc-5327174)
- 2024-03-05 21:44 UTC [SEC Form PRE 14A] [SEC Form PRE 14A filed by Merrimack Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-pre-14a-filed-by-merrimack-pharmaceuticals-inc-5318431)
- 2024-02-14 21:20 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Merrimack Pharmaceuticals Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-merrimack-pharmaceuticals-inc-amendment-5263674)
- 2024-02-13 21:50 UTC [Market Chatter] [Ipsen's Onivyde Regimen, A Potential New Standard-Of-Care First-Line Therapy In Metastatic Pancreatic Adenocarcinoma, Approved By FDA](https://www.quantisnow.com/insight/ipsens-onivyde-regimen-a-potential-new-standard-of-care-first-line-therapy-in-5255534)
- 2024-02-13 21:26 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Merrimack Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-merrimack-pharmaceuticals-inc-5255114)
- 2024-02-13 21:25 UTC [Market Chatter] [Merrimack Management Estimates That The Aggregate Amount Of The Liquidating Dividend Payable To Stockholders Will Be In The Range Of Between Approximately $14.65 And $15.35 Per Share](https://www.quantisnow.com/insight/merrimack-management-estimates-that-the-aggregate-amount-of-the-liquidating-5255093)
- 2024-02-13 21:24 UTC [Market Chatter] [Merrimack Says Ipsen's FDA Approval Of Onivyde sNDA Triggers $225M Payment From Ipsen to Merrimack](https://www.quantisnow.com/insight/merrimack-says-ipsens-fda-approval-of-onivyde-snda-triggers-225m-5255081)
- 2024-02-13 21:22 UTC [SEC Form 8-K] [Merrimack Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure](https://www.quantisnow.com/insight/merrimack-pharmaceuticals-inc-filed-sec-form-8-k-regulation-fd-disclosure-5255059)
- 2024-02-13 21:18 UTC [Dividends] [Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)](https://www.quantisnow.com/insight/merrimack-reports-ipsen-announcement-of-approval-by-the-us-fda-5254948)
- 2024-02-13 18:31 UTC [Market Chatter] [BZ NOTE: Merrimack Pharmaceuticals, As Part Of Its Agreement With Ipsen For The Sale Of Its Oncology Assets Including ONIVYDE, Is Eligible To Receive Additional Payments With The Possibility Of Up To $450M Contingent Upon The Approval Of Potential New Indications For ONIVYDE In The U.S.](https://www.quantisnow.com/insight/bz-note-merrimack-pharmaceuticals-as-part-of-its-agreement-with-5253869)
- 2024-02-13 18:19 UTC [Market Chatter] [FDA Approves Irinotecan Liposome For First-line Treatment Of Metastatic Pancreatic Adenocarcinoma](https://www.quantisnow.com/insight/fda-approves-irinotecan-liposome-for-first-line-treatment-of-metastatic-pancreatic-5253837)
- 2024-01-25 21:05 UTC [SEC Schedule 13D] [SEC Form SC 13D/A filed by Merrimack Pharmaceuticals Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13da-filed-by-merrimack-pharmaceuticals-inc-amendment-5208102)
- 2023-12-28 21:05 UTC [Insider Buy] [Andersen Eric bought $651,754 worth of shares (49,550 units at $13.15) (SEC Form 4)](https://www.quantisnow.com/insight/andersen-eric-bought-651754-worth-of-shares-49550-units-at-5157590)
- 2023-12-13 21:05 UTC [SEC Schedule 13D] [SEC Form SC 13D/A filed by Merrimack Pharmaceuticals Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13da-filed-by-merrimack-pharmaceuticals-inc-amendment-5135656)
- 2023-12-12 11:46 UTC [Market Insight] [$2M Bet On Ford? Check Out These 4 Stocks Insiders Are Buying](https://www.quantisnow.com/insight/2m-bet-on-ford-check-out-these-4-stocks-insiders-5131493)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/MACK
- Earnings history: https://www.quantisnow.com/earnings/MACK
- Dividend history: https://www.quantisnow.com/dividends/MACK
- Insider transactions: https://www.quantisnow.com/insiders/MACK
- Options chain: https://www.quantisnow.com/options/MACK
- SEC 8-K filings only: https://www.quantisnow.com/company/MACK/8-k
- RSS and alerts for MACK: https://www.quantisnow.com/docs/rss-feeds.md